iCAD to Participate in the LD Micro Main Event XVII
iCAD, a global leader in AI-powered breast health solutions, announced its participation in the LD Micro Main Event XVII on October 29-30, 2024, at the Luxe Sunset Boulevard Hotel, California. CEO Dana Brown will deliver a company presentation on Tuesday, October 29, at 10:30 a.m. PT / 1:30 p.m. ET and will be available for one-on-one meetings during the conference.
iCAD's mission is to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions. The company is listed on NASDAQ under the ticker symbol ICAD. Interested parties can register to watch the presentation virtually through the provided link.
iCAD, leader globale nelle soluzioni per la salute mammaria potenziate dall'IA, ha annunciato la sua partecipazione al LD Micro Main Event XVII, che si terrà il 29-30 ottobre 2024, presso il Luxe Sunset Boulevard Hotel in California. Il CEO Dana Brown presenterà l'azienda martedì 29 ottobre, alle 10:30 PT / 13:30 ET e sarà disponibile per incontri individuali durante la conferenza.
La missione di iCAD è quella di creare un mondo in cui il cancro non possa nascondersi, fornendo soluzioni clinicamente testate per la salute mammaria potenziate dall'IA. L'azienda è quotata alla NASDAQ con il simbolo ticker ICAD. Le parti interessate possono registrarsi per assistere alla presentazione in modalità virtuale tramite il link fornito.
iCAD, líder global en soluciones de salud mamaria impulsadas por IA, anunció su participación en el LD Micro Main Event XVII que se llevará a cabo el 29 y 30 de octubre de 2024 en el Luxe Sunset Boulevard Hotel, California. El CEO Dana Brown realizará una presentación de la empresa el martes 29 de octubre, a las 10:30 a.m. PT / 1:30 p.m. ET y estará disponible para reuniones uno a uno durante la conferencia.
La misión de iCAD es crear un mundo donde el cáncer no pueda esconderse mediante la provisión de soluciones de salud mamaria impulsadas por IA que han demostrado su eficacia clínica. La empresa está listada en la NASDAQ bajo el símbolo de ticker ICAD. Las partes interesadas pueden registrarse para ver la presentación virtualmente a través del enlace proporcionado.
iCAD, AI 기반 유방 건강 솔루션의 글로벌 리더, 2024년 10월 29일부터 30일까지 캘리포니아의 Luxe Sunset Boulevard Hotel에서 열리는 LD Micro Main Event XVII에 참가한다고 발표했습니다. CEO Dana Brown는 10월 29일 화요일 오전 10:30 PT / 오후 1:30 ET에 회사 발표를 진행하며, 컨퍼런스 기간 동안 1:1 미팅도 가능합니다.
iCAD의 사명은 임상적으로 입증된 AI 기반 유방 건강 솔루션을 제공하여 암이 숨지 못하는 세상을 만드는 것입니다. 이 회사는 NASDAQ에 ICAD라는 티커 심볼로 상장되어 있습니다. 관심 있는 분들은 제공된 링크를 통해 프레젠테이션을 가상으로 시청하기 위해 등록할 수 있습니다.
iCAD, leader mondial dans les solutions de santé mammaire alimentées par l'IA, a annoncé sa participation au LD Micro Main Event XVII qui se tiendra les 29 et 30 octobre 2024 à l'Hôtel Luxe Sunset Boulevard, en Californie. Le PDG Dana Brown présentera l'entreprise le mardi 29 octobre, à 10h30 PT / 13h30 ET et sera disponible pour des réunions individuelles pendant la conférence.
La mission d'iCAD est de créer un monde où le cancer ne peut pas se cacher, en fournissant des solutions cliniquement prouvées pour la santé mammaire alimentées par l'IA. L'entreprise est cotée sur le NASDAQ sous le symbole boursier ICAD. Les parties intéressées peuvent s'inscrire pour regarder la présentation virtuellement via le lien fourni.
iCAD, ein weltweit führendes Unternehmen für KI-gestützte Lösungen im Bereich Brustgesundheit, gab seine Teilnahme am LD Micro Main Event XVII bekannt, das am 29. und 30. Oktober 2024 im Luxe Sunset Boulevard Hotel in Kalifornien stattfinden wird. CEO Dana Brown wird am Dienstag, den 29. Oktober, um 10:30 Uhr PT / 13:30 Uhr ET eine Unternehmenspräsentation halten und wird während der Konferenz für persönliche Gespräche zur Verfügung stehen.
Die Mission von iCAD ist es, eine Welt zu schaffen, in der Krebs sich nicht verstecken kann, indem klinisch erprobte, KI-gestützte Lösungen für die Brustgesundheit bereitgestellt werden. Das Unternehmen ist an der NASDAQ unter dem Tickersymbol ICAD gelistet. Interessierte Parteien können sich über den bereitgestellten Link registrieren, um die Präsentation virtuell zu verfolgen.
- None.
- None.
Nashua, New Hampshire--(Newsfile Corp. - October 16, 2024) - iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, announced today that management is participating in the LD Micro Main Event XVII on October 29-30, at the Luxe Sunset Boulevard Hotel, California.
CEO Dana Brown will deliver a company presentation at 10:30 a.m. PT / 1:30 p.m. ET on Tuesday, October 29, and will be available for one-on-one meetings during the conference.
Interested parties can register to watch the presentation virtually at https://me24.sequireevents.com/.
About iCAD, Inc.
iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCAD's industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly
About LD Micro
LD Micro, a wholly owned subsidiary of Freedom US Markets, was founded in 2006 with the sole purpose of being an independent resource in the micro-cap space. Through the LD Micro Index and annual investor conferences, LD has served as an invaluable asset to all those interested in discovering the next generation of great companies. For more information on LD Micro, visit www.ldmicro.com.
Forward-Looking Statements
Certain statements contained in this News Release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expansion of access to the Company's products, improvement of performance, acceleration of adoption, expected benefits of ProFound AI®, the benefits of the Company's products, and future prospects for the Company's technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company's ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe," "demonstrate," "intend," "expect," "estimate," "will," "continue," "anticipate," "likely," "seek," and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC's website at http://www.sec.gov.
CONTACTS
Media inquiries:
pr@icadmed.com
Investor Inquiries:
John Nesbett/Rosalyn Christian
IMS Investor Relations
icad@imsinvestorrelations.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/226710
FAQ
When is iCAD (ICAD) participating in the LD Micro Main Event XVII?
Who will be presenting for iCAD (ICAD) at the LD Micro Main Event XVII?
What time is iCAD's (ICAD) presentation at the LD Micro Main Event XVII?
Where is the LD Micro Main Event XVII being held?
Can I watch iCAD's (ICAD) presentation at the LD Micro Main Event XVII virtually?
